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Background: TKM-130803 is a speciﬁc anti-EBOV therapeutic comprised of two small interfering RNAs
(siRNA) siLpol-2 and siVP35-2. The pharmacokinetics (PK) of these siRNAs was deﬁned in Ebola virus disease
(EVD) patients, with reference to efﬁcacy (ET) and toxicology thresholds (TT). The relationship between PK
and patient survival was explored.
Methods: Pharmacokinetic (PK) and pharmacodynamic (PD) data were available for seven participants with
EVD in Sierra Leone who received 0¢3 mg/kg of TKM-130803 by intravenous infusion over 2 h daily for up to
7 days. Plasma concentration of siRNA was compared to survival at 14 days. PK data were ﬁtted to two-com-
partment models then Monte Carlo simulated PK proﬁles were compared to ET (Cmax 0¢040¢57 ng/mL and
mean concentration 1¢43 ng/mL), and TT (3000 ng/mL).
Findings: Viral loads (VL) were not signiﬁcantly different at treatment onset or during treatment (p = 0¢1) in
subjects who survived or died. siRNA was in quantitative excess of virus genomes throughout treatment, but
the 95% percentile exceeded TT. The maximum AUC for which the 95% percentile remained under TT was a
continuous infusion of 0¢15 mg/kg/day. Plasma concentration of both siRNAs were higher in subjects who
died compared to subjects who survived (p<0¢025 both siRNAs).
Interpretation: TKM-130803 was circulating in molar excess of circulating virus; a level considered needed for
efﬁcacy. Given extremely high viral loads it seems likely that the patients died because they were physiologi-
cally beyond the point of no return. Subjects who died exhibited some indication of impaired drug clearance,
justifying caution in dosing strategies for such patients. This analysis has given a useful insight into the phar-
macokinetics of the siRNA in the disease state and illustrates the value of designing PKPD studies into future
clinical trials in epidemic situations.
Funding: This work was supported by the Wellcome Trust of Great Britain (grant number 106491/Z/14/Z and
097997/Z/11/A) and by the EU FP7 project PREPARE (602525). The PHE laboratory was funded by the UK
Department for International Development. The funders had no role in trial design, data collection or analy-
sis. The views expressed are those of the authors and not necessarily those of Public Health England, the
Department of Health, or the EU.
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Research in context
Evidence before this study
Tekmira (TKM-130803) is an anti-EBOV therapeutic comprised
of two small interfering RNAs (siRNA) which inhibit viral repli-
cation. Tekmira had successfully protected nonhuman primates
from EVD and had undergone safety studies in healthy humans.
A trial in EVD subjects in Sierra Leone in 2015 was discontin-
ued, because there was a low probability of overall therapeutic
beneﬁt. PK studies are invaluable in considering whether alter-
native doses or delivery regimens might have been more effec-
tive or less toxic. Drug concentrations overtime can be
markedly different in patients compared to healthy volunteers,
so it is important to carry out these studies in patients. PK stud-
ies are extremely challenging during an outbreak, so PK studies
were not included in other clinical trials.
Sources
This study was informed by previously published literature,
sourced by searching online databases using the following key
words: Tekmira, TKM, siRNA, Ebola, EBOV, EVD. It was also
informed by the investigator’s brochure provided by the manu-
facturer, and WHO recommendations on the characterisation
and prioritisation of drugs for consideration or use in patients
infected with Ebola.
Added value of this study
This study proved that collecting sufﬁcient samples to develop a
PK mathematical model was possible in the context of an Ebola
outbreak. Subjects had extremely high levels of circulating Ebola
virus, over twice that reported in the Zmapp study. The concen-
tration of drug in subjects who died was higher than in subjects
who survived, probably because their organs were failing and
less able to clear the drug from their body. There were more cop-
ies of siRNA in circulation than there were viruses, however the
mathematical model indicated that higher dose of drug, even
given over a longer period would have unacceptably increased
the risk of adverse events.
Implications of all the available evidence
Policy: PK studies are possible during an Ebola outbreak, yield-
ing useful results with relatively few subjects.
Practice: A cautious approach to dosing in advanced EVD
patients is warranted, and a reduced drug clearance should be
assumed in such patients.
Future research: Future clinical trials should aim to recruit sub-
jects with a range of viral loads and consider a stratiﬁed
approach to analysis. siRNA type therapeutics remain
unproven, but promising agents for treating EVD and warrant
further study.
Relevance to human health: Integrating PK studies into clinical
trials for high consequence pathogens should facilitate effective
and dose optimised therapeutics.
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The efﬁcacy of TKM-130803 for the treatment of Ebola virus dis-
ease (EVD) was trialled in a single arm phase II trial in laboratory con-
ﬁrmed EVD subjects in Sierra Leone during the 201416 Ebola-Zaire
(Makona) outbreak [1,2]. TKM products are formulations of two small
interfering RNAs (siRNA) encapsulated by four lipids to formPlease cite this article as: J.T. Scott et al., Pharmacokinetics of TKM-13
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tion was developed for the intravenous (IV) delivery of the siRNA
component into the cytoplasm of cells. TKM-130803 comprises of
two siRNA molecules siLpol-2 and siVP35-2 in a 1:1 mixture by
weight and molarity. The two siRNAs silence expression of EBOV
mRNA-dependent L polymerase (Lpol), and Viral Protein 35 (VP35)
respectively. The siRNAs enhance host mediated viral mRNA destruc-
tion thereby inhibiting Ebola virus (EBOV) replication (Fig. 1) [35].
This report describes the pharmacokinetics of siLpol-2 and siVP35-2
in EVD patients and explores the relationship between the pharma-
cokinetics (PK) of these molecules and survival. It also reports PK
models for the siRNAs in EVD patients developed from the clinical
trial data.
TKM-130803 was rapidly formulated at the beginning of the West
African outbreak, to make a bespoke product with sequence align-
ment with the West African Ebola-Zaire (Makona), which caused the
201416 outbreak [1,6]. Its combined siRNA component was termed
siEbola-3. TKM-130803 was developed from precursor investiga-
tional medicinal products (IMPs), TKM 100201 and TKM-100802
which were studied prior to the outbreak in post exposure prophy-
laxis models of Ebola-Zaire infections (EBOV-Zaire). TKM 100201 and
TKM-100802 contained siRNA components with sequence align-
ments to the Kikwit strain of EBOV-Zaire (termed siEbola-2) [5,6].
The reformulation from siEbola-2 to siEbola-3 involved two nucleo-
tide substitutions in the VP35 siRNA and one nucleotide substitution
in the siLpol-2 [1,3,6]. Decisions regarding dose and regimen for the
clinical trial were based on preclinical and healthy volunteer data for
TKM-100201 and TKM-100802. Unfortunately the improved LNP2
which was used in conjunction with siEbola-3 to protect EBOV-
infected non-human primates (NHPs) was not available for use in the
clinical trial, which used LNP1 [6,7].
The dose for the current study was conservative, chosen with
reference to toxicology data from TKM 100201 and TKM-100802
to maximize safety. In a dose-escalation, healthy volunteer study,
one (of two) participants dosed at the highest level of 0¢5 mg/kg
experienced cytokine release syndrome, so the maximal dose was
limited to 0¢3 mg/kg/day [3,8]. Two patients who contracted EVD
in West Africa were treated subsequently with TKM-100802 in
the United States. The ﬁrst patient was treated with doses starting
at 0¢3 mg/kg/day and rising to 0¢5 mg/kg/day for 14 days. The sec-
ond patient was treated with an unspeciﬁed dose for 6 days. No
drug-related serious adverse events were reported in these
patients [9]. NHPs were safely dosed at much higher levels
(0¢52¢0 mg/kg/day) using the improved LNP2 formulation [57].
The European Medicines Agency recommended that a dose of
0¢2 mg/kg/day may be effective in humans based on a series of
experiments in NHPs and in vitro data [8]. The number of days post
challenge was critical in determining the survival beneﬁt of TKM-
100802. Five out of six animals (83¢3%) treated with TKM-100802
24 h post infection and three out of six treated 48 h post infection
survived. When TKM-100802 was given 72 h after infection, four out
of six (66¢7%) animals survived. However, when TKM-100802 was
given 96 h after infection, zero out of six animals survived [8]. siE-
bola-3 formulated with a LNP2 resulted in 100% survival (3/3) in rhe-
sus monkeys infected with a lethal challenge of Makona variant
EBOV. NHPs were dosed at 0¢5 mg/kg/day for 7 days, commencing
72 h post-inoculation, a point in the disease course where viral RNA
levels are typically 106 RNA copies/ml [6].
The current PKPD study was embedded within a clinical trial of
TKM-130803 carried out in EVD patients in Sierra Leone in 2015.
0¢3 mg/kg of TKM-130803 was given daily. The trial was discontinued
having reached a predeﬁned statistical endpoint which indicated a
low probability of demonstrating overall therapeutic beneﬁt com-
pared to historic controls [1]. This has to be interpreted in the context
of the exceptionally high mean pre-treatment viral loads in the trial
(>1 £ 109 RNA copies /ml plasma); over twice that seen in the trial of
0803 in Sierra Leonean patients with Ebola virus disease: plasma
ost severe patients, EBioMedicine (2020), https://doi.org/10.1016/j.
Fig. 1. Mechanism of LNP-Mediated RNA Interface [22].
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human studies have been used to set efﬁcacy and toxicity thresholds.
This is the ﬁrst published study to our knowledge with sufﬁcient PK
data measured during an Ebola outbreak, to produce a PK in silico
model.2. Methods
2.1. Ethics statement and data sharing
The trial [1,2] was approved by the Sierra Leone Ethics and Scien-
tiﬁc Review Committee, and the Oxford Tropical Research Ethics
Committee. Approval to conduct the trial and import the trial drug
was granted by the Pharmacy Board of Sierra Leone. The Committee
for Medicinal Products for Human Use of the European Medicines
Agency was asked for an opinion on the use of TKM-130803 in
humans with EVD and was of the view that conducting a clinical trial
of TKM-130803 in the context of the Ebola outbreak was acceptable.
The UK Department for International Development and GOAL Global
approved for the trial to be conducted at the Port Loko Ebola treat-
ment centre (ETC). An independent data monitoring committee
(IDMC) reviewed data on a sequential basis and reviewed any
reported adverse events or other safety concerns. The trial was con-
ducted in compliance with the International Conference on Harmoni-
sation guidance on good clinical practice, and the Pharmacy Board of
Sierra Leone conducted a good clinical practice compliance inspec-
tion during the trial. Written informed consent was obtained for all
participants. The original data set is available on request.2.1.1. Trial design
Fourteen participants with EVD were recruited into the clinical trial
to receive the 0¢3 mg/kg of TKM-130803 by intravenous infusion over
2 h once daily for up to 7 days. Blood was collected pre- and post-
administration of TKM-130803 on days 1, 3, 5, and 7, and plasma was
separated by centrifugation and stored in aliquots, for both quantiﬁca-
tion of viral load and quantiﬁcation of drug in the plasma. For drug
quantiﬁcation the samples Trizol LS was added to plasma before being
frozen at 80 °C for later shipping and evaluation. Plasma was avail-
able for quantiﬁcation of drug concentrations for eight subjects, withPlease cite this article as: J.T. Scott et al., Pharmacokinetics of TKM-13
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Further details of trial design are reported here [1].
2.1.2. Quantiﬁcation of viral loads
Viral RNA was extracted using the Qiagen EZ1TM Virus Mini Kit in
combination with the EZ1TM Advanced XL Automated Puriﬁcation
System, then quantiﬁed using the Trombley Ebola Diagnostic assay
[10], as used by Public Health England for diagnostics in Ebola Treat-
ment Centres. Positive, negative and extraction controls were
included as standard for each quantiﬁcation for quality control.
2.1.3. Quantiﬁcation of siRNA concentrations
To detect the concentration of siLpol-2 and siVP35-2, total RNA
was extracted from the plasma using a partial Trizol TM LS Reagent
(Invitrogen) extraction method. Plasma was mixed with Trizol LS at
the time of collection. At the time of quantiﬁcation, samples were
thawed and centrifuged, then the aqueous phase, containing the
drug, was collected then hybridised to complementary oligonucleoti-
des (siVP35-2 or siLpol Capture Probe and Detection Probe, Exiqon),
ﬁrst a biotinylated “capture” probe, then a digoxigenin-labelled
“detection” probe. Hybridized samples were transferred to Neutravi-
din-coated, black-walled microtitre plate (Pierce), and incubated to
allow capture of the complexes. Plates were washed, then anti-digox-
igenin conjugated to alkaline phosphatase (Roche Biochemicals)
added, followed by the addition of AttoPhos substrate (Promega) for
a ﬂuorometric readout. Plates were read using a BioTek FLx800
reader and analysed using BioTek Gen5 Data Analysis software. The
calibration range of the assay is 0¢5100 ng/mL, while the quantiﬁca-
tion range is 1100 ng/mL. Samples outside this range were diluted
as required in sample diluent (Trizol LS reagent, human K2EDTA
plasma) before the repeating the extraction and hybridization pro-
cess. Quality control samples containing 3, 50 and 80 ng/mL diluted
in sample diluent were included in each assay. All QC and standards
were expected to be within 20% of the theoretical values for the
assay.
2.1.4. Clinical data collection
Subjects were categorized according to survival at 14 days, which
was the primary endpoint of the clinical trial [1]. Due to the restraints
intrinsic in collecting timed blood draws from EVD subjects, the exact0803 in Sierra Leonean patients with Ebola virus disease: plasma
ost severe patients, EBioMedicine (2020), https://doi.org/10.1016/j.
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draw was noted in the clinical trial record. Viral load at T0 was calcu-
lated by interpolating viral load measured in the pre-dose and post
dose samples. ‘Time zero (T0)’ for each subject was deﬁned as the
time at which the initial dose of TKM-130803 was commenced. The
area under the viral load curve was calculated using the trapezioidal
method with Stata IC version 15 (Statacorp, Texas) for the period of
treatment (7 days) after T0 or until death, whichever came ﬁrst. Since
the time of follow up necessarily varied, AUC/hour was used for com-
parison between subjects. Comparisons of subjects who survived to
the 14-day endpoint ‘Survived’ and those who did not ‘Died’ was car-
ried out using Mann-Whitney-U comparison of mean ranks using
Stata IC version 15. For reference, 1 ng siPol-2 = 4¢21 £ 1010 Mole-
cules, 1 ng suVP35-2 = 4¢20 £ 1010 molecules, thus a 1:1 ratio by
weight equates to molar equivalent in the lipid nanoparticle.
Molecular excess was shown from calculation of the number of
molecules of siRNA component compared to the number of mole-
cules of virus. The number molecules of siRNA was calculated from
mass per mL and molecular mass of the siRNA component and num-
ber of virus molecules was calculated as above.
2.1.5. PK thresholds
Peak and mean concentrations of siRNA components were com-
pared to the efﬁcacy thresholds predicted from in vitro experiments
using TKM-100802: EC50 (WT Kikwit 1995 strain): 0¢040¢57 ng/mL
and EC90 (GFP-EBOV Mayinga variant strain) 1¢43 ng/mL [11]. For the
purpose of this exercise we assumed that efﬁcacy is driven by AUC,
and toxicity by Cmax. The dose and regimen that would maximise
AUC, with a Cmax of 3000 ng/ml was considered. This threshold is
the minimum 50% cytotoxic concentration (CC50) level for Hep2G
cells, henceforth referred to as the “CC50 threshold” over a seven day
treatment period [11].
2.1.6. Pharmacokinetic model
Population pharmacokinetic modelling, calculation of area under the
curve (AUC) values for each siRNA, and simulations, were performed
using Pmetrics [12] within R version 3.1.0. Separate PK models were
built for both siLpol-2 and siVP35-2 components of TKM-130803.
The ﬁnal structural models for both siLpol-2 and siVP35-2 incor-
porated a two-compartment model with infusion of the TKM-130803
component in to the central compartment (Fig. 2) as detailed by the
differential Eqs. (1a) and (1b):
dX1
dt
¼ kpcX2 CLV
 
X1kcpX1 ð1aÞ
dX2
dt
¼ kcpX1kpcX2 ð1bÞ
where X1 and X2 are the amounts of siLpol-2 or siVP35-2 respec-
tively in the central and peripheral compartments, representing wellFig. 2. A representation of a two compartment model as used for both siRNA simula-
tions. SiRNA is infused into the central compartment and out according to constant of
elimination (Ke). The ﬁrst order rate constants of distribution from and to the central
compartment denoted by Kcp and Kpc, respectively.
Please cite this article as: J.T. Scott et al., Pharmacokinetics of TKM-13
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organs, respectively. The pharmacokinetic parameters CL and V
denote the clearance and volume of distribution, respectively. kcp and
kpc represent the ﬁrst order rate constants of distribution from and to
the central compartment.
Model ﬁtting was performed using protocols deﬁned previously
[13,14]. Brieﬂy, the goodness-of-ﬁt of the observed/predicted values
(population and individual predictions) were assessed by linear
regression (intercept close to 0, slope close to 1), the coefﬁcient of
determination of the linear regression (R2 close to 1¢0) and log-likeli-
hood values; plots for ﬁnal models are shown in Fig. 3. The ratio
achieved of siRNA molecules: genomes of viral load was calculated
compared in the Survived and Died subjects.
Monte Carlo simulation of 1000 individuals using the PK models
for siLpoL-2 and VP35, was performed to simulate a) the standard
dose (0¢3 mg/kg/day) in a 2 h infusion for purposes of a visual predic-
tive check (VPC) and at 0¢5 and 1 times the standard dose in a contin-
uous infusion regimen designed to maximise drug exposure, whilst
minimising peak drug concentrations. PK proﬁles were compared to
efﬁcacy and toxicology thresholds (supplementary information). We
extrapolated a pharmacokinetic target from previous data. We con-
sidered which dose and regimen would maximise the AUC, with a
Cmax of 3000 ng/ml (minimum CC50 DLT for Hep2G cells) and mini-
mise the peak concentration using an infused dose over a seven-day
treatment period.
3. Results
3.1. Observed PK and PD parameters
Viral load (VL) was measured at a median of 1¢18 h before T0
(when treatment was commenced) (IQR: 3¢4 to 0¢8 h) and again a
median of 2¢22 h after T0 (IQR 2¢07 to 2¢65). The PCR cycle threshold
(cT) value was log-linearly related to VL. Log10 VL ranged from 8¢04
to 9¢49 (median 8¢79, IQR 8¢42 to 9¢36).
Viral load at T0, was lower in subjects who survived compared to
those who died but this difference was not statistically signiﬁcant
(p = 0¢099) (Fig. 4(A)). The viral load remained lower in those who
survived: the AUC of VL per hour was lower in subjects who survived
compared to those who died, again this difference was not statisti-
cally signiﬁcant (p = 0¢10) (Fig. 4(B)). The concentration of both siR-
NAs was signiﬁcantly higher in subjects who died compared to those
who survived, probably indicating poorer drug clearance in their
advanced disease state. The AUC of siLpol-2 and siVP35-2 per hour
was signiﬁcantly higher in subjects who died compared to subjects
who survived (p<0¢025 for both siRNA) (Fig. 4(C) and (D)). The asso-
ciated median levels for Fig. 4 and IQR are in Supplementary Material
Table 1. This is also observed in considering the relationship between
change in viral load from initial dose to last recorded viral load and
viral AUC per hour.
There was a molar excess of both siRNAs over the course of treat-
ment in the plasma (Fig. 5), however the ratio of siRNA molecules/
genomes was not signiﬁcantly different between those who died and
those who survived (siLpol-2: p = 0¢88; siVP35-2: p = 0¢65). Two sub-
jects had markedly higher ratios of molecule/genome (subjects #2,
who died and #3 who survived). The highest ratio of molecule/
genome was 221,677.8 (siPol-2, in subject #2) and 1,183,506 (VP35-2
in subject #3).
3.2. The PK model
Two compartment models were ﬁtted to siLpol-2 and siVP35 con-
centrations using population pharmacokinetic analysis. There were
excellent correlations between observed and predicted values for
these models (Fig. 3). PK parameters for two compartment models
for silpol-2 and siVP35 are shown in Supplementary Material Table 1,0803 in Sierra Leonean patients with Ebola virus disease: plasma
ost severe patients, EBioMedicine (2020), https://doi.org/10.1016/j.
Fig. 3. Predicted versus observed concentrations for individual and population prediction for siLpol-2: (A) and (B) and siVP35: (C) and (D). R2 values for siLpol-2 were determined to
be 0¢90 and 0¢53 for individual (A) and population (B) predictions. For siVP35 R2 was determined to be 0¢91 and 0¢52 for individual (C) and population (D) predictions.
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higher for siLpol-2 than for siVP35 (12¢43 ml/h/kg and 56¢69 ml/kg
and compared to 3¢39 mL/h/kg and 16¢69 mL/h). This indicates that
siVP35 will display greater drug accumulation in EVD patients than
siLpol-2. Elimination rate constants were determined to be similar
for the two siRNA components, as were rate constants to and from
the peripheral compartment.
3.3. In silico simulated PK in the context of preclinical data
Simulations of the PK of TKM-130803 in patients in the current
trial exceed the in vitro efﬁcacy thresholds of 0¢040¢57 ng/mL and
1¢43 ng/mL (EC50 and EC90) [11] by several orders of magnitude in all
patients in the current clinical trial at the standard dose (0¢3 mg/kg/
day) (Fig. 6(A) and (B)).
3.3.1. Median concentrations at a dose of 0¢3 mg/kg/day infused once a
day over 2 h
The median peak concentrations achieved by siLpoL-2 (Fig. 6(A))
and siVP35 (Fig. 6(B)) in patients using a 0¢3 mg/kg/day TKM-130803
dosage regimen were lower than the CC50 threshold. Dosing in the
current trial reproduced Cmax values consistent with those predicted
in the NHP models using TKM-100802 for siLpol-2, with the median
peak concentration being in line with Cmax values from NOAEL for
repeat dosing (Fig. 6(A)). The simulated median peak concentrations
(Cmax) were: 1471 ng/mL (IQR: 756 ng/mL) for siLpol-2 and
4585 ng/mL (IQR: 2936 ng/mL) for siVP35. There was morePlease cite this article as: J.T. Scott et al., Pharmacokinetics of TKM-13
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siVP35 was slightly above the repeat dose NOAEL Cmax level
observed in NHPs, using the 0¢3 mg/kg/day TKM-130803 dosage regi-
men.
3.3.2. percentile concentrations at a dose of 0¢3 mg/kg/day infused once
a day over 2 h
Drug accumulated more in patients who died than those who sur-
vived (Fig. 4(C) and (D)). This is likely to have driven the accumula-
tion over time of drug seen reﬂected in the 95th percentile of the
overall PK simulation (Fig. 6(A) and (B)). The 95th percentile
exceeded the CC50 threshold for both siPol-2 and VP35. Despite this,
no adverse events were observed during the clinical trial [1].
3.3.3. Simulating an increase in infusion time
AUC can be maintained with lowering in peak drug concentration
using longer infusion times. Taking this to its extreme for illustration
we considered a continuous infusion for 7 days instead of a 2 h infu-
sion once a day for 7 days. For siLpol-2 the AUC remained the same
for the daily 2-h infusion and the continuous infusion for 7 days from
60,609 ng*h/mL (IQR: 97,606 ng*h/mL) (2 h infusion) to 58,515 ng*h/
mL (IQR: 94,606 ng*h/mL), (continuous infusion) over the 7 day
period. The simulated peak concentrations for the two regimens are
however markedly different: median values 1471 ng/mL (IQR:
757 ng/mL) for the standard regimen and 603 ng/mL (IQR: 932 ng/
mL) for continuous infusion. For siVP35 the AUC for the daily 2-hour
infusion and the continuous infusion for 7 days are: 239,690 ng*h/mL0803 in Sierra Leonean patients with Ebola virus disease: plasma
ost severe patients, EBioMedicine (2020), https://doi.org/10.1016/j.
Fig. 4. A comparison of viral load and component siRNA strands of TKM-130803 compared by outcome (survived or died) A: log10VL at T0 B: log10 (AUC of VL) C: AUC/hr siLpol-2 D:
AUC/hr siVP35-2. Median values depicted by a horizontal line.
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6 J.T. Scott et al. / EBioMedicine 00 (2020) 102601(IQR: 265,040 ng*h/mL)(2 h infusion), and 233,743 ng*h/mL (IQR:
253,205 ng*h/mL) (continuous infusion), respectively. The simulated
peak concentrations for the two regimens are again markedly differ-
ent, with median values 4585 ng/mL (IQR: 2936 ng/mL) for the stan-
dard regimen and 2373 ng/mL (IQR: 3023 ng/mL) for the continuous
infusion (Fig. 6).
The maximum possible dose for which the 95% percentile
remained under the CC50 threshold was an infusion of 0¢15 mg/Kg/
day (Fig. 6(E) and (F)). This resulted in an AUC of 29,141 ng*hr/mL
(IQR: 47,374) for siPol-2 and 116,812 (IQR: 126,441) for VP35, with
Cmax median values of 342 ng/mL (IQR: 466 ng/mL) and 1223 ng/mL
(IQR: 1507 ng/mL) (Fig. 6).
4. Discussion
TKM was tested in preclinical trials in NHPs within hours of being
inoculated with Ebola virus with good effect [5]. Whilst it is disap-
pointing that a drug which looked so promising in NHPs would not
prove efﬁcacious in a human trial [1], the preclinical NHP data pre-
dicted success in a challenge of up to 106 RNA copies/ml EBOV with
TKM dosed at 0¢5 mg/kg/day within 72 h of infection [15] It is impor-
tant that when TKM-100802 was given 96 h after infection, 0/6 ani-
mals survived [8]. EVD patients often present to Ebola treatment
centres several days after onset of symptoms, between 2 and 21 days
post infection [16]. Pre-treatment viral loads in the clinical trial were
above 109 RNA copies/ml1 (over twice that reported in the ZMappPlease cite this article as: J.T. Scott et al., Pharmacokinetics of TKM-13
concentrations exceed target levels, with drug accumulation in the m
ebiom.2019.102601study [7]). Patients treated with TKM-130803 in Sierra Leone, may
have presented too late for an antiviral to have an effect. The viral
loads tested in the human trial far exceeded that tested in animal
models and at which time, end-stage organ damage was irreversible
[1,17]. Supporting this hypothesis: Viral loads of >8 log10 copies ml1
were 90% predictive of a fatal outcome in the 20002001 SUDV
Gulu outbreak [18]. However the serial sampling of PKPD samples
has permitted an insight into pharmacokinetics in the disease state
which could be useful for future trials of siRNAs or other anti-Ebola
therapeutics [1,7].
PK has been deployed with utility for other EVD therapeutics,
most notably Favipiravir which compared drug concentrations to a
model developed from healthy human volunteers [19]. However the
current study is the only EVD therapeutic to date with both PK and
PD information from human subjects with acute EVD, from which an
in silico PK model has been published. The severe haemodynamic dis-
truption caused by EVD, culminating in multi-organ failure [20] is
likely to alter the PK of any drug administered to a patient, compared
to the PK in a healthy subject.
In this study, the number of molecules of either siRNA (siLpol-2
and siVP35-2) of TKM-130803 in plasma exceeded the number of
Ebola virus genomes per ml throughout treatment in all subjects
assessed. We propose that this suggests there was sufﬁcient siRNA to
be effective. However, this may not reﬂect the ratio at the site of
action, which is intracellular. The highest drug/viral load ratio
achieved was 1 £ 106 molecules/genome. Prior to treatment and
0803 in Sierra Leonean patients with Ebola virus disease: plasma
ost severe patients, EBioMedicine (2020), https://doi.org/10.1016/j.
Fig. 5. siPol-2 & siVP35-2 (Molecules/ml), and Viral Load (VL) (genomes/ml) proﬁles over time per subject.
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Fig. 6. Simulated pharmacokinetic proﬁles based on 1000 simulated individuals for different TKM regimens from population models based on clinical pharmacokinetic data. Simu-
lated concentration proﬁles of (A) siLpol-2 and (B) siVP35 for once daily 2 h infusion of 0¢3 mg/Kg/day total TKM (0¢15 mg/Kg/day siLpol-2 or siVP35). Simulated concentration pro-
ﬁle of (C) siLpol-2 and (D) siVP35 for continuous infusion regimen of 0¢3 mg/kg/day total TKM (0¢15 mg/kg/day siLpol-2/siVP35). Simulated concentration proﬁle of (E) siLpol-2 and
F) siVP35 for continuous infusion regimen of 0¢15 mg/Kg/day total TKM (0¢075 mg/kg/day siLpol-2/siVP35). Black solid lines represent median simulated drug concentration proﬁles
and red dashed lines represent 5th and 95th percentile concentration proﬁles, respectively. Grey circles in proﬁles A and B represent observed drug concentrations from sparse
plasma sampling. Horizontal solid and dashed grey lines represent the upper and lower limits of the cytotoxic concentration (CC50) as determined in Hep2G cells.
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8 J.T. Scott et al. / EBioMedicine 00 (2020) 102601throughout disease, there was no statistically signiﬁcant difference in
viral load between subjects who subsequently survived or died,
although there was a non-signiﬁcant trend for those who died to
have higher viral loads. This is consistent with the small number of
patients in the same treatment centre who were not treated [1] and
with observations in the wider epidemic [21].Please cite this article as: J.T. Scott et al., Pharmacokinetics of TKM-13
concentrations exceed target levels, with drug accumulation in the m
ebiom.2019.102601Both siRNA concentrations were signiﬁcantly higher over the
course of treatment in subjects who died. Explanations for this
include: (1) patients who died had impaired drug clearance, or, since
the siRNA function intracellularly, (2) cellular uptake was lower
resulting in higher concentrations of circulating drug. The LPD cap-
sule was designed to protect the siRNAs rapid renal clearance to0803 in Sierra Leonean patients with Ebola virus disease: plasma
ost severe patients, EBioMedicine (2020), https://doi.org/10.1016/j.
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ing renal failure are predictive of mortality [20,23], therefore either
impared renal clearance or cellular uptake are feasible hypothesis for
higher concentrations of circulating drug. A third possibility is that
those who died suffered more drug related toxicity. However given
that no drug related serious adverse reactions were detected, includ-
ing cytokine release syndrome, and viral loads were high at admis-
sion and remained high over time in patients who died, it is likely
that the association between high TKM-130803 concentrations and
death is a reﬂection of impaired drug clearance in sicker patients or
impaired cellular uptake, rather than drug related toxicity [24].
Higher plasma drug concentrations, by either mechanism, may put
participants with more advanced disease at a greater risk of a serious
adverse event.
The trial used a dose of TKM-130803 that was determined to bal-
ance safety and potential clinical beneﬁt. Cytokine release syndrome
was observed as an adverse event in one healthy volunteer from an
earlier Phase 1 trial of TKM-100802 [3,7], which resulted in the rec-
ommended dose being reduced from 0¢5 mg/kg/d to 0¢3 mg//kg/day.
Cytokine release syndrome was not observed in any participant in
this trial of TKM-130803 at a dose of 0¢3 mg/kg/day [1]. Dose selec-
tion was also informed, in part, by the need for a single daily, short
infusion, due to the logistical difﬁculties in supervising an intrave-
nous infusion of an experimental drug in an Ebola Treatment Unit [2]
and the NOAEL observed in NHPs. The high mortality and morbidity
associated with EVD could have justiﬁed using a higher dose, but
with a greater risk of adverse events [4,25]. As a thought experiment,
PK curves were simulated as continuous infusions; an idealised situa-
tion in which the AUC can be maintained whilst minimising peak
drug concentrations. Although impractical in the real world, this
served to indicate that using the PK observed in these patients, a
higher dose could not have been used without breaching the toxicol-
ogy threshold. The PKPD data from participants in this trial indicate
that plasma concentrations of TKM-130803 were in substantial molar
excess of viral RNA, and clearance was impaired, suggesting the con-
servative approach was justiﬁed.
It remains possible that TKM-130803 could be efﬁcacious if used
as a post-exposure prophylaxis or is commenced earlier in the dis-
ease process, in which case it is likely that a higher dose could be tol-
erated in patients with intact drug clearance. We suggest that future
drug trials for siRNA, or other therapeutics stratify analysis by pre-
treatment viral load. The safety of dosing high viral load patients
with advanced disease should be considered assuming reduced drug
clearance, and a commensuratly higher propensity to adverse effects.
siRNA-type therapeutics have the advantage that they can be swiftly
developed and produced in response to previously unknown viruses
or strains of viruses [15]. Given their novel targets, they could be
used synergistically with other drug types. The lipid nanoparticle
(LNP) technique in particular continues to be improved: siRNAs are
protected from degradation by plasma and tissue nucleases and facil-
itate intracellular uptake of the nanoparticle by endocytosis prevent-
ing the rapid clearance of the siRNAs [22]. A recent reformulation,
using a VP35-targeting siRNA with a new lipid nanoparticle compo-
nent, has achieved 100% survival of NHPs challenged with Ebola-
Sudan, even when the animals were dosed 5 days after infection,
although animals with viral loads greater than 8¢9 log10 GEq ml1
succumbed [15].
That this drug was not efﬁcacious in human subjects with severe
EVD using a conservative dosing regimen does not preclude the pos-
sibility that an alternative dose, given earlier, a different regimen, or
using an improved lipid nanoparticle formulation might have some
efﬁcacy. It seems likely that the patients in the clinical trial with
extremely high viral loads, died because they were physiologically
beyond the point of no return. We propose that efﬁcacy of TKM
130803 was neither proved nor disproved by the clinical trial, butPlease cite this article as: J.T. Scott et al., Pharmacokinetics of TKM-13
concentrations exceed target levels, with drug accumulation in the m
ebiom.2019.102601that it has given a useful insight into the pharmacokinetics of the
siRNA in the disease state [1].RAPIDE-TKM trial team
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